Upstream Bio vs Vistagen Therapeutics
UPB and VTGN side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.
How UPB and VTGN compare
Upstream Bio is the larger company, worth 25 times as much as Vistagen Therapeutics ($187M against $7.5M).
Vistagen Therapeutics keeps more of each dollar of sales as profit, with a net margin of −2703% compared with −4956% at Upstream Bio.
Key numbers
A dot marks the better figure where higher or lower is clearly better.
| Metric | UPB | VTGN |
|---|---|---|
| Size and price | ||
| Market cap | $187M | $7.5M |
| Share price | $3.41 | $0.168 |
| Change, 1 year | −85.9% | −95.8% |
| Change, 5 years | – | −99.8% |
| Beta (5Y) | 1.47 | 1.29 |
| Employees | 75 | 41 |
| StockData Score | ||
| Total score | 9 | 9 |
| Valuation score | 1 | 3 (better) |
| Growth score | 1 (better) | 0 |
| Performance score | 1 | 1 |
| Health score | 6 (better) | 5 |
| Dividend score | 0 | 0 |
| Valuation | ||
| P/S | 59.1× | 3.0× (better) |
| P/B | 0.7× | 0.3× (better) |
| Fair value | – | $0.874 |
| Margin of safety | – | 80.7% |
| Growth | ||
| Revenue growth (TTM) | 16.0% | – |
| Revenue growth, 5Y average | – | 3.1% |
| Profitability | ||
| Operating margin | −5383% | −2784% (better) |
| Net margin | −4956% | −2703% (better) |
| Return on equity | −46.0% (better) | −166% |
| Return on invested capital | −1082% | – |
| Financial health | ||
| Debt / equity | 0.00 | 0.00 |
| Current ratio | 27.99 (better) | 3.07 |
| Altman Z-score | 8.07 (better) | −24.40 |
| Piotroski F-score | 1 | 2 (better) |
| Dividends and buybacks | ||
| Shareholder yield | 0.00% | 0.00% |
| Ownership | ||
| Held by institutions | 92.3% | 26.5% |
| Held by insiders | 8.6% | 0.52% |
| Insider net buying, 12 months | −$105K | – |
| Short interest, % of float | 9.0% | 8.5% |
Go deeper
- UPB stock overview
- UPB income statement
- UPB valuation and score
- VTGN stock overview
- VTGN income statement
- VTGN valuation and score
For information only, not investment advice. Check the source filings before relying on any figure.